Filing Flows › Aquestive Therapeutics (AQST) › License and Royalty Revenue revenue
Aquestive Therapeutics (AQST) License and Royalty Revenue revenue by quarter
Aquestive Therapeutics' License and Royalty Revenue revenue was $824K in Q3 2026 (third quarter 2026), -38% from Q2 2026. Over the last 6 quarters it ranged from $790K (Q1 2025) to $5.4M (Q1 2026).
| Quarter | License and Royalty Revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $824K | -38% | -21% |
| Q2 2026 | $1.3M | -75% | — |
| Q1 2026 | $5.4M | +533% | +583% |
| Q4 2025 | $852K | -18% | — |
| Q3 2025 | $1.0M | +31% | — |
| Q1 2025 | $790K | — | — |
Q3 2026 at a glance
Aquestive Therapeutics, Q3 2026: revenue $7.6M (-41% year over year), operating margin -191.5%, net loss $16.5M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Aquestive Therapeutics' License and Royalty Revenue revenue?
Aquestive Therapeutics' License and Royalty Revenue revenue was $824K in Q3 2026 (third quarter 2026), -38% from Q2 2026.
How has Aquestive Therapeutics' License and Royalty Revenue revenue changed?
Over the last 6 quarters it ranged from $790K (Q1 2025) to $5.4M (Q1 2026).
Q3 2026 results → · How Aquestive Therapeutics makes money →